Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (1058)	3/4/2000 11:00:00 PM
From: John Goodman	Read Replies (3) \| Respond to of 1386

Cacaito: It is my understanding that Aviv was so encouraged with P2C3 results that he recently made this known to the public. Not the details, mind you but the general essence of P2C3 results. It is also my understanding that P3, not the previously planned P2/P3, studies are under way due primarily to these recent stellar P2C3 results. Are my facts out of whack or did I just read Aviv incorrectly? As for valuation, you are probably right about the ophthalmics. However, these days, investors are paying premiums for potential returns. With Aviv publicly giving us a "thumbs-up" on P2C3, I do not see a significant dip in share price for a while. If Aviv is not telling stories, the market will value HU-211 at share prices far better than we see today. You can guess where this leads. John